已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Cannabidiol suppresses 3-dimensional ovarian cancer growth and may enhance potency of classic and epigenetic therapies

球体 大麻酚 卵巢癌 医学 顺铂 表观遗传学 效力 癌症 紫杉醇 癌症研究 揭穿 全景望远镜 体内 卡铂 肿瘤科 药理学 内科学 化疗 细胞培养 生物 体外 大麻 遗传学 精神科 基因 组蛋白脱乙酰基酶 组蛋白
作者
Courtney Griffiths,James Aikins,Olga Ostrovsky,David Warshal
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:162: S102-S103 被引量:1
标识
DOI:10.1016/s0090-8258(21)00838-6
摘要

Objectives: High-grade serous ovarian cancer (HGSOC) is the leading cause of death from gynecological cancer in the US. The majority of patients will present at advanced stage and will recur due to chemoresistance. New therapeutic strategies such as epigenetic and cannabinoid-based therapies may help circumvent this chemoresistance problem. We aim to determine the potency of clinically relevant concentrations of CBD monotherapy as well as combined with epigenetic (ET) and classic chemotherapy on tumor formation and propagation in 3-Dimensional (3D) ovarian cancer (OC) spheroid models. Methods: We created our clinically relevant 3D spheroid tissue culture model in order to mimic physiological conditions in vivo with platinum sensitive OC cell lines. Spheroids were treated with both one time and chronic doses of cannabidiol (CBD) at pre-determined concentrations alone or in combination with chemotherapeutic and epigenetic drugs (Cisplatin/Paclitaxel, Panobinostat). Spheroid growth and morphology were evaluated over an extended time kinetic (days 0, 3, 6, 10/12) and measured by volume of growth. The average radius of the spheroids was used to calculate the spheroid volume according the formula V = 4/3 πr3 and was monitored for percent growth relative to spheroid size at the beginning of the experiment (day 0). Microscopic pictures were taken to follow the morphologic changes. Results: Over an extended kinetic, high and medium concentrations of one time CBD (CBDH) tended to stunt spheroid growth in comparison to control, (686% and over 700% less growth). Low concentrations of one time CBD (CBDL) had a lessened effect on spheroid growth, (556% less growth). Classic chemotherapy combined with CBD contributed to a decreased overall spheroid growth, and even shrinkage with one time CBDL (34% shrinkage versus 84% growth in C/T group) over an extended kinetic. Chronic CBDH administration resulted in greater than 7500% less growth by day 10. Chronic CBDL in combination with C/T resulted in a 99% less growth in comparison to C/T by day 6. One time CBD administration with Panobinostat (Pano) decreased the amount of growth over a shorter kinetic (18% and 2% shrinkage for Pano/CBDL and Pano/CBDM, respectively, versus 13% growth for Pano). With the application of chronic CBD, Pano and CBD resulted in shrinkage early on and even 100% lysis of 3D OC by day 10. Conclusions: As demonstrated by our results, clinically relevant concentrations of CBD possess antitumorigenic effects on OC cells. Further, our data using the combination of Panobinostat with varying concentrations of CBD leads us to hypothesize that a one-time dose of CBD is not sufficient for prolonged antitumorigenic effects, with a synergistic effect demonstrated by chronic administration of CBD. Regarding classic chemotherapy and the effect of varying concentrations of CBD, our data indicates a synergistic effect exists with low concentrations of CBD. Further studies are indicated to determine whether these synergistic effects can aid in the reversal of chemoresistance and enhance the efficacy of targeted treatments. High-grade serous ovarian cancer (HGSOC) is the leading cause of death from gynecological cancer in the US. The majority of patients will present at advanced stage and will recur due to chemoresistance. New therapeutic strategies such as epigenetic and cannabinoid-based therapies may help circumvent this chemoresistance problem. We aim to determine the potency of clinically relevant concentrations of CBD monotherapy as well as combined with epigenetic (ET) and classic chemotherapy on tumor formation and propagation in 3-Dimensional (3D) ovarian cancer (OC) spheroid models. We created our clinically relevant 3D spheroid tissue culture model in order to mimic physiological conditions in vivo with platinum sensitive OC cell lines. Spheroids were treated with both one time and chronic doses of cannabidiol (CBD) at pre-determined concentrations alone or in combination with chemotherapeutic and epigenetic drugs (Cisplatin/Paclitaxel, Panobinostat). Spheroid growth and morphology were evaluated over an extended time kinetic (days 0, 3, 6, 10/12) and measured by volume of growth. The average radius of the spheroids was used to calculate the spheroid volume according the formula V = 4/3 πr3 and was monitored for percent growth relative to spheroid size at the beginning of the experiment (day 0). Microscopic pictures were taken to follow the morphologic changes. Over an extended kinetic, high and medium concentrations of one time CBD (CBDH) tended to stunt spheroid growth in comparison to control, (686% and over 700% less growth). Low concentrations of one time CBD (CBDL) had a lessened effect on spheroid growth, (556% less growth). Classic chemotherapy combined with CBD contributed to a decreased overall spheroid growth, and even shrinkage with one time CBDL (34% shrinkage versus 84% growth in C/T group) over an extended kinetic. Chronic CBDH administration resulted in greater than 7500% less growth by day 10. Chronic CBDL in combination with C/T resulted in a 99% less growth in comparison to C/T by day 6. One time CBD administration with Panobinostat (Pano) decreased the amount of growth over a shorter kinetic (18% and 2% shrinkage for Pano/CBDL and Pano/CBDM, respectively, versus 13% growth for Pano). With the application of chronic CBD, Pano and CBD resulted in shrinkage early on and even 100% lysis of 3D OC by day 10. As demonstrated by our results, clinically relevant concentrations of CBD possess antitumorigenic effects on OC cells. Further, our data using the combination of Panobinostat with varying concentrations of CBD leads us to hypothesize that a one-time dose of CBD is not sufficient for prolonged antitumorigenic effects, with a synergistic effect demonstrated by chronic administration of CBD. Regarding classic chemotherapy and the effect of varying concentrations of CBD, our data indicates a synergistic effect exists with low concentrations of CBD. Further studies are indicated to determine whether these synergistic effects can aid in the reversal of chemoresistance and enhance the efficacy of targeted treatments.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
学海行舟完成签到 ,获得积分10
3秒前
13秒前
14秒前
nicenice发布了新的文献求助10
19秒前
咕噜噜完成签到,获得积分10
23秒前
闫雪发布了新的文献求助10
24秒前
25秒前
29秒前
30秒前
Simpson完成签到 ,获得积分10
33秒前
www发布了新的文献求助10
34秒前
我是老大应助ceeray23采纳,获得20
37秒前
李爱国应助zzzkyt采纳,获得10
40秒前
lb001完成签到 ,获得积分10
42秒前
zzjjyy完成签到,获得积分10
43秒前
小刘发布了新的文献求助10
46秒前
48秒前
zzzkyt完成签到,获得积分10
48秒前
万能图书馆应助www采纳,获得10
51秒前
zzzkyt发布了新的文献求助10
52秒前
Hyh_orz应助onlyan采纳,获得20
53秒前
54秒前
55秒前
霜鸣完成签到,获得积分20
55秒前
霜鸣发布了新的文献求助10
1分钟前
1分钟前
lynn完成签到,获得积分10
1分钟前
xiaoleihu完成签到 ,获得积分10
1分钟前
singber完成签到,获得积分10
1分钟前
龙猫爱看书完成签到,获得积分10
1分钟前
ceeray23发布了新的文献求助20
1分钟前
梦醒了完成签到 ,获得积分10
1分钟前
111111完成签到,获得积分10
1分钟前
赘婿应助科研通管家采纳,获得10
1分钟前
xdlongchem完成签到,获得积分10
1分钟前
eee完成签到 ,获得积分10
1分钟前
cherlie完成签到,获得积分10
1分钟前
1分钟前
1分钟前
2213sss完成签到,获得积分10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990012
求助须知:如何正确求助?哪些是违规求助? 3532047
关于积分的说明 11256141
捐赠科研通 3270918
什么是DOI,文献DOI怎么找? 1805105
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216